Multiple Sclerosis Clinical Trials

Multiple Sclerosis (MS) is a complex, chronic disease affecting the central nervous system, which includes the brain, spinal cord, and optic nerves. It is characterized by the immune system mistakenly attacking the protective sheath (myelin) that covers nerve fibers, causing communication problems between the brain and the rest of the body. Eventually, the disease can cause permanent damage or deterioration of the nerves.

Over the years, advancements in research have led to a better understanding of the pathophysiological mechanisms of MS, allowing for more targeted therapeutic approaches. The evolution of treatment strategies from broad immunosuppressive therapies to more specific immunomodulatory drugs reflects the growing understanding of the disease's complex nature.


Approximately

2.8M

people worldwide are affected by MS

 


Women are about

2x

as likely as men to be diagnosed with MS

 

The onset of MS symptoms often occurs in young adulthood, typically between the ages

20-40

 

Our clinical team has over

120

years of combined clinical trial experience

 

Download Our Paper

Fill out this form to download our white paper on how to overcome the biggest obstacles in conducting a multiple sclerosis clinical trial.

iNGENū CRO - Multiple Sclorosis

In light of the significant impact multiple sclerosis has on individuals and society as a whole, continued research and awareness efforts are crucial to improve diagnosis, treatment, and ultimately, the quality of life for those living with this disease.

The development of clinical trial protocols that meet FDA approval standards is crucial for the success of new multiple sclerosis treatments.